Enjoy complimentary customisation on priority with our Enterprise License!
The cell therapy market share is expected to increase by USD 21.061 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 56.79%.
This cell therapy market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers cell therapy market segmentation by type (autologous and allogenic), application (malignancies, musculoskeletal, cardiovascular, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)). The cell therapy market report also offers information on several market vendors, including Astellas Pharma Inc., Athersys Inc., Avita Medical Inc., BioCardia Inc., Bone Therapeutics SA, Brainstorm Cell Therapeutics Inc., Bristol-Myers Squibb Co., Caladrius Biosciences Inc., Capricor Therapeutics Inc., Castle Creek Biosciences Inc., CellPraxis, CellSeed Inc., Cellular Biomedicine Group Inc., Celyad Oncology SA, Gilead Sciences Inc., Lineage Cell Therapeutics Inc., Mesoblast Ltd., Novartis AG, Pharmicell Co. Ltd., Sanpower Group Co. Ltd., ThermoGenesis Holdings Inc., and Vericel Corp. among others.
Download the Free Report Sample to Unlock the Cell Therapy Market Size for the Forecast Period and Other Important Statistics
"The limitations in traditional organ transplantations fueling demand for stem cell therapies will facilitate the autologous cell therapy market growth in North America over the forecast period."
The increasing prevalence of chronic diseases is notably driving the cell therapy market growth, although factors such as high cost and failure rate in clinical trials may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the cell therapy industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Cell Therapy Market Driver
The increasing prevalence of chronic diseases is one of the key drivers supporting the cell therapy market growth. Most chronic diseases may result in tissue or organ damage. The vast majority of treatments available for chronic diseases are palliative. In contrast, other treatment options can delay disease progression and the onset of complications associated with the underlying illness. Meanwhile, regenerative medicine opens the possibility of overcoming previously untreatable diseases using new treatment methods such as processed cells for reconstructing tissues. It has the unique capability of altering the fundamental mechanisms of diseases. It also helps in reducing healthcare costs by eliminating the need for long-term hospitalization or drug regimes. This is leading to the increased adoption of cell therapies for the treatment of chronic diseases, which, in turn, is driving the focused market growth.
Key Cell Therapy Market Trend
Increasing focus on cell therapy products is another factor supporting the cell therapy market growth. Amgen is currently developing Blinatumomab (Phase III candidate) for the treatment of B-cell Non-Hodgkin lymphoma. Bluebird bios drug candidate, LentiGlobin BB305 drug product, is currently in its Phase III development stage for the treatment of sickle cell disease. Also, Bristol-Myers Squibb reported positive results from its Phase II clinical trial of lenalidomide for the treatment of multiple myeloma. The drug is currently in its Phase III development stage. However, a few of the indications that are being evaluated include degenerative arthritis, knee osteoarthritis (Phase II), and knee osteoarthritis (Phase I). Thus, approval of new drugs in such areas will drive revenues, thereby positively impacting the market growth.
Key Cell Therapy Market Challenge
The high cost and failure rate in clinical trials are some of the factors hindering the cell therapy market growth. For instance, multiple clinical trials need to be conducted for testing biodistribution, appropriate dosing, delivery timing, tumorigenicity associated with the administered stem cells, and immune rejection. Also, the development of a robust proof-of-concept preclinical model can be costly because it may involve immunomodulation to match the human immune system. A major challenge is a difficulty in recruiting a sufficient number of patients, which results in delays and indirectly translates to an increase in clinical trial costs. Moreover, following the strict regulatory guidelines for compliance in clinical trials is one of the main challenges that companies are facing which will restrict the market growth.
This cell therapy market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global cell therapy market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the cell therapy market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the cell therapy market encompasses successful business strategies deployed by the key vendors. The cell therapy market is fragmented and the vendors are deploying growth strategies such as quality, price, market reach, and financial resources to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The cell therapy market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the cell therapy market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
40% of the market's growth will originate from North America during the forecast period. The US is the key market for cell therapy market in North America. Market growth in this region will be slower than the growth of the market in Asia.
The growing number of regenerative medicine centers will facilitate the cell therapy market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
.The outbreak of COVID-19 in 2020 in the region accelerated R and D activities, especially in the US. In addition, in the same year, the Government of Canada invested around $6.9 million in regenerative medicine research through the Stem Cell Networks competitive research funding program, which supports some of the country's most promising stem cell research. This funding will create new pipelines of drugs and create opportunities for partnerships and investments for further clinical development and testing. Thus, with an increase in such projects, the demand for cell therapy will increase in the region during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The cell therapy market share growth by the autologous segment will be significant during the forecast period. The autologous cell therapy segment is expected to benefit from the increasing government funding for R and D, the rising prevalence of chronic diseases, and the increasing focus of vendors on developing effective cell therapy products. This therapy has an established presence in the dermatology and musculoskeletal disorders segments. Also, there has been a growing focus of vendors on developing novel treatments for emerging applications such as cardiology and ophthalmology.b Such growing factors will drive market growth during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the cell therapy market size and actionable market insights on post COVID-19 impact on each segment.
Cell and Gene Therapy market - The market share is expected to increase by USD 9.97 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 20.15%.
Autologous Cell Therapy market - The market share is expected to increase by USD 4.11 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 14.16%.
Stem Cell Therapy market - The market size has the potential to grow by USD 588.22 mn during 2020-2024, and the market's growth momentum will accelerate during the forecast period.
CAR T-cell Therapy market - The market share is expected to register a CAGR close to 63% in the 2018-2022 forecast period
|
Cell Therapy Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 56.79% |
|
Market growth 2022-2026 |
$ 21.061 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
56.3 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 40% |
|
Key consumer countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
Astellas Pharma Inc., Athersys Inc., Avita Medical Inc., BioCardia Inc., Bone Therapeutics SA, Brainstorm Cell Therapeutics Inc., Bristol-Myers Squibb Co., Caladrius Biosciences Inc., Capricor Therapeutics Inc., Castle Creek Biosciences Inc., CellPraxis, CellSeed Inc., Cellular Biomedicine Group Inc., Celyad Oncology SA, Gilead Sciences Inc., Lineage Cell Therapeutics Inc., Mesoblast Ltd., Novartis AG, Pharmicell Co. Ltd., Sanpower Group Co. Ltd., ThermoGenesis Holdings Inc., and Vericel Corp. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Market Segmentation by Application
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Vendor Landscape
11 Vendor Analysis
12 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
